RBOT Fundamental Analysis - VICARIOUS SURGICAL INC-A

Fundamental Rating

Overall RBOT gets a fundamental rating of 2 out of 10. We evaluated RBOT against 187 industry peers in the Health Care Equipment & Supplies industry. While RBOT has a great health rating, there are worries on its profitability. RBOT is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

RBOT had negative earnings in the past year.

In the past year RBOT has reported a negative cash flow from operations.

RBOT had negative earnings in 4 of the past 5 years.

RBOT had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of RBOT (-182.62%) is worse than 91.44% of its industry peers.

With a Return On Equity value of -380.42%, RBOT is not doing good in the industry: 79.68% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-182.62%
ROE	-380.42%
ROIC	N/A

ROA(3y)-49.66%

ROA(5y)-48.14%

ROE(3y)-67.76%

ROE(5y)-64.37%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

RBOT has a Gross Margin of 5.76%. This is amonst the worse of the industry: RBOT underperforms 83.96% of its industry peers.

The Profit Margin and Operating Margin are not available for RBOT so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	5.76%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

RBOT does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, RBOT has more shares outstanding

RBOT has less shares outstanding than it did 5 years ago.

There is no outstanding debt for RBOT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

RBOT has an Altman-Z score of -15.67. This is a bad value and indicates that RBOT is not financially healthy and even has some risk of bankruptcy.

RBOT has a worse Altman-Z score (-15.67) than 85.56% of its industry peers.

There is no outstanding debt for RBOT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-15.67

ROIC/WACCN/A

WACC8.8%

2.3 Liquidity

A Current Ratio of 4.75 indicates that RBOT has no problem at all paying its short term obligations.

RBOT has a better Current ratio (4.75) than 75.40% of its industry peers.

A Quick Ratio of 4.75 indicates that RBOT has no problem at all paying its short term obligations.

With an excellent Quick ratio value of 4.75, RBOT belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	4.75
Quick Ratio	4.75

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.05% over the past year.

Looking at the last year, RBOT shows a very strong growth in Revenue. The Revenue has grown by 160.31%.

EPS 1Y (TTM)12.05%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%35.86%

Revenue 1Y (TTM)160.31%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RBOT will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.21% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y24.7%

EPS Next 2Y25.51%

EPS Next 3Y18.21%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RBOT. In the last year negative earnings were reported.

Also next year RBOT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as RBOT's earnings are expected to grow with 18.21% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y25.51%

EPS Next 3Y18.21%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for RBOT!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

VICARIOUS SURGICAL INC-A

NYSE:RBOT (12/18/2025, 8:04:00 PM)

After market: 2.21 0 (0%)

2.21

-0.17 (-7.14%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)11-12 2025-11-12/amc

Earnings (Next)03-16 2026-03-16/amc

Inst Owners28.43%

Inst Owner Change-6.96%

Ins Owners2.3%

Ins Owner Change-0.03%

Market Cap14.48M

Revenue(TTM)21.69M

Net Income(TTM)-53.59M

Analysts77.78

Price Target9.18 (315.38%)

Short Float %3.21%

Short Ratio1.22

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)17.03%

Min EPS beat(2)12.43%

Max EPS beat(2)21.62%

EPS beat(4)3

Avg EPS beat(4)11.32%

Min EPS beat(4)-2.78%

Max EPS beat(4)21.62%

EPS beat(8)5

Avg EPS beat(8)11.53%

EPS beat(12)8

Avg EPS beat(12)11.45%

EPS beat(16)9

Avg EPS beat(16)9.44%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-10%

PT rev (3m)-10%

EPS NQ rev (1m)11.66%

EPS NQ rev (3m)24.87%

EPS NY rev (1m)7.61%

EPS NY rev (3m)11.56%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.67
P/FCF	N/A
P/OCF	N/A
P/B	1.03
P/tB	1.03
EV/EBITDA	N/A

EPS(TTM)-9.05

EYN/A

EPS(NY)-4.61

Fwd EYN/A

FCF(TTM)-7.31

FCFYN/A

OCF(TTM)-7.26

OCFYN/A

SpS3.31

BVpS2.15

TBVpS2.15

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-182.62%
ROE	-380.42%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	5.76%
FCFM	N/A

ROA(3y)-49.66%

ROA(5y)-48.14%

ROE(3y)-67.76%

ROE(5y)-64.37%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0.74

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.75
Quick Ratio	4.75
Altman-Z	-15.67

F-Score3

WACC8.8%

ROIC/WACCN/A

Cap/Depr(3y)193.53%

Cap/Depr(5y)211.75%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)12.05%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%35.86%

EPS Next Y24.7%

EPS Next 2Y25.51%

EPS Next 3Y18.21%

EPS Next 5YN/A

Revenue 1Y (TTM)160.31%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-13.17%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year51.85%

EBIT Next 3Y23.49%

EBIT Next 5YN/A

FCF growth 1Y32.57%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y31.43%

OCF growth 3YN/A

OCF growth 5YN/A

VICARIOUS SURGICAL INC-A / RBOT FAQ

What is the ChartMill fundamental rating of VICARIOUS SURGICAL INC-A (RBOT) stock?

ChartMill assigns a fundamental rating of 2 / 10 to RBOT.

What is the valuation status for RBOT stock?

ChartMill assigns a valuation rating of 0 / 10 to VICARIOUS SURGICAL INC-A (RBOT). This can be considered as Overvalued.

How profitable is VICARIOUS SURGICAL INC-A (RBOT) stock?

VICARIOUS SURGICAL INC-A (RBOT) has a profitability rating of 0 / 10.

What is the expected EPS growth for VICARIOUS SURGICAL INC-A (RBOT) stock?

The Earnings per Share (EPS) of VICARIOUS SURGICAL INC-A (RBOT) is expected to grow by 24.7% in the next year.

VICARIOUS SURGICAL INC-A (RBOT) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

VICARIOUS SURGICAL INC-A / RBOT FAQ

What is the ChartMill fundamental rating of VICARIOUS SURGICAL INC-A (RBOT) stock?

What is the valuation status for RBOT stock?

How profitable is VICARIOUS SURGICAL INC-A (RBOT) stock?

What is the expected EPS growth for VICARIOUS SURGICAL INC-A (RBOT) stock?